Proof of Concept Study Evaluating BP1.3656 in Patients With Fatigue Following Ischemic Stroke
A Multisite Randomized Clinical Trial Evaluating Efficacy and Safety of BP1.3656 vs Placebo in Patients With Fatigue Following Ischemic Stroke
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Stéphanie Renaux
- Phone Number: +33147036633
- Email: s.renaux@bioprojet.com
Study Contact Backup
- Name: Martine Le Gall
- Phone Number: +33147036633
- Email: m.legall@bioprojet.com
Study Locations
-
-
-
Bordeaux, France, 33076
- Hôpital Pellegrin - CHU Bordeaux
-
-
-
-
-
Berne, Switzerland, 3010
- Inselspital Berne
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Males or females 18 years old or more;
- Diagnosis of ischemic stroke at least one month and not more than six months prior to screening;
- Persistent fatigue since the stroke with a score ≥ 50 across all domains of the Multidimensional Fatigue Inventory (MFI-20);
- Modified Rankin Score (mRS) < 3;
- Capability to participate in all study tests according to the investigator;
- Patient must voluntarily express a willingness to participate in this study, sign and date an informed consent prior to any study specific procedure;
- Females of child-bearing potential must have a negative pregnancy test performed at the screening and randomization visits and use a medically accepted effective method of birth control, agree to continue this method for the duration of the study up until three weeks after last treatment intake.
Exclusion Criteria:
- Any identified etiology for fatigue other than stroke (except post-stroke depression) according to the investigator;
- History of psychosis;
- Current severe psychiatric disorder, e.g. schizophrenia, bipolar disorder, severe depression, or organic brain syndrome preventing the patients from completing study assessments;
- Patients at risk of suicide according to the investigator;
- Major cognitive disorders, dementia according to the investigator;
- History of epilepsy or seizures disorder;
- History of alcohol or drugs (i.e. cannabis, cocaine, amphetamines or opioids) (ab)use/dependence within the 12 months prior to screening or with a positive drug test at screening;
- Glomerular filtration rate <60 mL/min/1.73m² according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula;
- Clinically significant cardiovascular abnormalities (including clinically relevant ECG abnormalities) or, clinically significant hematological, neurological, endocrine abnormalities, severe hepatic impairment or Liver Function Tests (ASAT, ALAT) > 3 ULN, or abnormal clinical laboratory results (in most cases > 3ULN);
- Other active clinically significant illness, infection, acid-related gastric disorder, or neoplastic pathology within the last 3 years (patients with fully cured non-melanoma skin cancer or in-situ carcinoma of the cervix are eligible) which could interfere with the study conduct or counter-indicate the study treatments or place the patient at risk during the trial or compromise his/her study participation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: BP1.3656
1 tablet of 30 microgram (µg), 60µg or 90µg of BP1.3656 per day
|
Histamine H3 receptor antagonist/inverse agonist
|
|
Placebo Comparator: Placebo
1 tablet of matching placebo per day
|
Histamine H3 receptor antagonist/inverse agonist
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Multidimensional Fatigue Inventory (MFI-20) global score
Time Frame: Week 8
|
20-item self-report instrument designed to measure fatigue experienced by the participant lately scored from 20 to 100.
Higher scores show higher levels of fatigue.
|
Week 8
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events (AEs) as assessed by AEs collection
Time Frame: Week 8
|
Safety assessment of BP1.3656 based on adverse events (AEs) reporting during treatment period.
|
Week 8
|
|
Change in Systolic blood pressure (BP) measurement
Time Frame: From baseline to Week 8
|
Safety assessment of BP1.3656 based on the measurement of systolic blood pressure in units of millimeters of mercury (mmHg)
|
From baseline to Week 8
|
|
Change in Diastolic blood pressure (BP) measurement
Time Frame: From baseline to Week 8
|
Safety assessment of BP1.3656 based on the measurement of Diastolic blood pressure in units of millimeters of mercury (mmHg)
|
From baseline to Week 8
|
|
Change in pulse
Time Frame: From baseline to Week 8
|
Safety assessment of BP1.3656 based on the measurement of pulse in beats/minute
|
From baseline to Week 8
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Claudio Bassetti, MD, Prof., Inselspital Bern, Department of Neurology, Bern, Switzerland
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- P20-04 / BP1.3656
- 2020-006006-23 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.